SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (352)6/15/2005 12:47:46 PM
From: tom popeRead Replies (1) | Respond to of 802
 
I don't know what wizardly powers you have Zeta, but clicking on that link shut down all browser windows!



To: zeta1961 who wrote (352)6/15/2005 2:17:05 PM
From: JibacoaRead Replies (2) | Respond to of 802
 
Re: Option exercises.

The executives that exercised their options to buy at $6.67/share were:

David Nance CEO & President 125,000 shares
James Albrecht , CFO 80,000 shares
David Enloe, Senior VP, 90,000 Shares
Max Talbot, VP, 90,000 shares
David Parker, VP. 65,000 shares
Robert Sobol, VP , 65,000 shares

Total: 515,000 shares were acquired by exercising options at $6.67/share.

Bernard


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News